|
1
|
Rawla P and Barsouk A: Epidemiology of
gastric cancer: Global trends, risk factors and prevention. Prz
Gastroenterol. 14:26–38. 2019.PubMed/NCBI
|
|
2
|
Machlowska J, Baj J, Sitarz M, Maciejewski
R and Sitarz R: Gastric Cancer: Epidemiology, risk factors,
classification, genomic characteristics and treatment strategies.
Int J Mol Sci. 21:40122020. View Article : Google Scholar
|
|
3
|
Balar AV, Galsky MD, Rosenberg JE, Powles
T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J,
Perez-Gracia JL, et al IMvigor210 Study Group, : Atezolizumab as
first-line treatment in cisplatin-ineligible patients with locally
advanced and metastatic urothelial carcinoma: A single-arm,
multicentre, phase 2 trial. Lancet. 389:67–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winawer SJ: Gastric cancer: Worldwide
burden and prevention opportunities. Chin J Dig Dis. 6:107–109.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ilson DH: Advances in the treatment of
gastric cancer. Curr Opin Gastroenterol. 33:473–476. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hess LM, Michael D, Mytelka DS, Beyrer J,
Liepa AM and Nicol S: Chemotherapy treatment patterns, costs, and
outcomes of patients with gastric cancer in the United States: A
retrospective analysis of electronic medical record (EMR) and
administrative claims data. Gastric Cancer. 19:607–615. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lordick F and Siewert JR: Recent advances
in multimodal treatment for gastric cancer: A review. Gastric
Cancer. 8:78–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zali H, Rezaei-Tavirani M and Azodi M:
Gastric cancer: Prevention, risk factors and treatment.
Gastroenterol Hepatol Bed Bench. 4:175–185. 2011.PubMed/NCBI
|
|
9
|
Liccardi G and Pentimalli F: Cancer,
immunity and inflammation. Report from the CDD Cambridge
Conferences 2018 and 2019. Cell Death Dis. 10:7982019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diakos CI, Charles KA, McMillan DC and
Clarke SJ: Cancer-related inflammation and treatment effectiveness.
Lancet Oncol. 15:e493–e503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kawanishi S, Ohnishi S, Ma N, Hiraku Y and
Murata M: Crosstalk between DNA Damage and Inflammation in the
Multiple Steps of Carcinogenesis. Int J Mol Sci. 18:18082017.
View Article : Google Scholar
|
|
13
|
Zamarron BF and Chen W: Dual roles of
immune cells and their factors in cancer development and
progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Del Prete A, Allavena P, Santoro G,
Fumarulo R, Corsi MM and Mantovani A: Molecular pathways in
cancer-related inflammation. Biochem Med (Zagreb). 21:264–275.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-kB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao J, Zhang H, Huang Y, Wang H, Wang S,
Zhao C, Liang Y and Yang N: Bay11-7082 attenuates murine lupus
nephritis via inhibiting NLRP3 inflammasome and NF-κB activation.
Int Immunopharmacol. 17:116–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Mao Z and Sun J: NF-κB inhibitor,
BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT
potential via miR-30a/NF-κB/Snail signaling in bladder cancer
cells. Gene. 710:91–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Xie J, Gan R, Wu Z, Luo H, Chen
X, Lu Y, Wu L and Zheng D: Synergistic inhibition of lung cancer
cells by EGCG and NF-κB inhibitor BAY11-7082. J Cancer.
10:6543–6556. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Viola K, Kopf S, Huttary N, Vonach C,
Kretschy N, Teichmann M, Giessrigl B, Raab I, Stary S, Krieger S,
et al: Bay11-7082 inhibits the disintegration of the
lymphendothelial barrier triggered by MCF-7 breast cancer
spheroids; the role of ICAM-1 and adhesion. Br J Cancer.
108:564–569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang CT, Liang Q, Yang L, Lin XL, Wu S,
Chen Y, Zhang XT, Gao YJ and Ge ZZ: RAB31 Targeted by miR-30c-2-3p
regulates the GLI1 signaling pathway, affecting gastric cancer cell
proliferation and apoptosis. Front Oncol. 8:5542018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu M, Ren L, Liang F, Zhang Y, Jiang L, Ma
W, Li C, Li X and Ye X: Effect of epiberberine from Coptis
chinensis Franch on inhibition of tumor growth in MKN-45 ×enograft
mice. Phytomedicine. 76:1532162020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Wang J, Fan JH, Zhang YQ, Zhao JX,
Dai XJ, Liu Q, Shen YJ, Liu C, Sun WD, et al: Ilexgenin A exerts
anti-inflammation and anti-angiogenesis effects through inhibition
of STAT3 and PI3K pathways and exhibits synergistic effects with
Sorafenib on hepatoma growth. Toxicol Appl Pharmacol. 315:90–101.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
García MG, Alaniz L, Lopes EC, Blanco G,
Hajos SE and Alvarez E: Inhibition of NF-kappaB activity by BAY
11-7082 increases apoptosis in multidrug resistant leukemic T-cell
lines. Leuk Res. 29:1425–1434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng X, Chang RL, Cui XX, Avila G, Huang
MT, Liu Y, Kong AN, Rabson AB and Conney AH: Inhibition of
NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile
(BAY11-7082; BAY) is associated with enhanced
12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and
apoptosis in human prostate cancer PC-3 cells. Int J Oncol.
32:257–264. 2008.PubMed/NCBI
|
|
26
|
Li B, Li YY, Tsao SW and Cheung AL:
Targeting NF-kappaB signaling pathway suppresses tumor growth,
angiogenesis, and metastasis of human esophageal cancer. Mol Cancer
Ther. 8:2635–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue W, Meylan E, Oliver TG, Feldser DM,
Winslow MM, Bronson R and Jacks T: Response and resistance to NF-κB
inhibitors in mouse models of lung adenocarcinoma. Cancer Discov.
1:236–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaife CL, Kuang J, Wills JC, Trowbridge
DB, Gray P, Manning BM, Eichwald EJ, Daynes RA and Kuwada SK:
Nuclear factor kappaB inhibitors induce adhesion-dependent colon
cancer apoptosis: Implications for metastasis. Cancer Res.
62:6870–6878. 2002.PubMed/NCBI
|
|
29
|
Keller SA, Hernandez-Hopkins D, Vider J,
Ponomarev V, Hyjek E, Schattner EJ and Cesarman E: NF-kappaB is
essential for the progression of KSHV- and EBV-infected lymphomas
in vivo. Blood. 107:3295–3302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dewan MZ, Terashima K, Taruishi M,
Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M,
et al: Rapid tumor formation of human T-cell leukemia virus type
1-infected cell lines in novel NOD-SCID/gammac(null) mice:
Suppression by an inhibitor against NF-kappaB. J Virol.
77:5286–5294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miyamoto R, Ito T, Nomura S, Amakawa R,
Amuro H, Katashiba Y, Ogata M, Murakami N, Shimamoto K, Yamazaki C,
et al: Inhibitor of IkappaB kinase activity, BAY 11-7082,
interferes with interferon regulatory factor 7 nuclear
translocation and type I interferon production by plasmacytoid
dendritic cells. Arthritis Res Ther. 12:R872010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia YT, Ma B, Wei W, Xu Y, Wang Y, Tang HT
and Xia ZF: Sustained activation of nuclear factor-kappaB by
reactive oxygen species is involved in the pathogenesis of
stress-induced gastric damage in rats. Crit Care Med. 35:1582–1591.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kumar A, Negi G and Sharma SS: Suppression
of NF-κB and NF-κB regulated oxidative stress and neuroinflammation
by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental
diabetic neuropathy. Biochimie. 94:1158–1165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Piechota A and Goraca A: Influence of
nuclear factor-κB inhibition on endothelin-1 induced lung edema and
oxidative stress in rats. J Physiol Pharmacol. 62:183–188.
2011.PubMed/NCBI
|
|
35
|
Terzioğlu G, Türksoy Ö and Bayrak ÖF:
Identification of An mtDNA Setpoint Associated with Highest Levels
of CD44 Positivity and Chemoresistance in HGC-27 and MKN-45 Gastric
Cancer Cell Lines. Cell J. 20:312–317. 2018.PubMed/NCBI
|
|
36
|
Peng Y, Liu YM, Li LC, Wang LL and Wu XL:
MicroRNA-503 inhibits gastric cancer cell growth and
epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Akagi T and Kimoto T: Human cell line
(HGC-27) derived from the metastatic lymph node of gastric cancer.
Acta Med Okayama. 30:215–219. 1976.PubMed/NCBI
|
|
38
|
Busuttil RA, Liu DS, Di Costanzo N,
Schröder J, Mitchell C and Boussioutas A: An orthotopic mouse model
of gastric cancer invasion and metastasis. Sci Rep. 8:8252018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kasperczyk H, Baumann B, Debatin KM and
Fulda S: Characterization of sonic hedgehog as a novel NF-kappaB
target gene that promotes NF-kappaB-mediated apoptosis resistance
and tumor growth in vivo. FASEB J. 23:21–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cai K, Na W, Guo M, Xu R, Wang X, Qin Y,
Wu Y, Jiang J and Huang H: Targeting the cross-talk between the
hedgehog and NF-κB signaling pathways in multiple myeloma. Leuk
Lymphoma. 60:772–781. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wei L, Yan N, Sun L, Bao C and Li D:
Interplay between the NF κB and hedgehog signaling pathways
predicts prognosis in esophageal squamous cell carcinoma following
neoadjuvant chemoradiotherapy. Int J Mol Med. 41:2961–2967.
2018.PubMed/NCBI
|
|
42
|
Chen M, Carkner R and Buttyan R: The
hedgehog/Gli signaling paradigm in prostate cancer. Expert Rev
Endocrinol Metab. 6:453–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xie H, Paradise BD, Ma WW and
Fernandez-Zapico ME: Recent Advances in the Clinical Targeting of
Hedgehog/GLI Signaling in Cancer. Cells. 8:3942019. View Article : Google Scholar
|
|
44
|
Wessler S, Krisch LM, Elmer DP and Aberger
F: From inflammation to gastric cancer - the importance of
Hedgehog/GLI signaling in Helicobacter pylori-induced chronic
inflammatory and neoplastic diseases. Cell Commun Signal.
15:152017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J
and Sung JJ: Dysregulation of cellular signaling in gastric cancer.
Cancer Lett. 295:144–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kasper M, Regl G, Frischauf AM and Aberger
F: GLI transcription factors: Mediators of oncogenic Hedgehog
signalling. Eur J Cancer. 42:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sasaki H, Nishizaki Y, Hui C, Nakafuku M
and Kondoh H: Regulation of Gli2 and Gli3 activities by an
amino-terminal repression domain: Implication of Gli2 and Gli3 as
primary mediators of Shh signaling. Development. 126:3915–3924.
1999.PubMed/NCBI
|
|
48
|
Lauth M and Toftgård R: Non-canonical
activation of GLI transcription factors: Implications for targeted
anti-cancer therapy. Cell Cycle. 6:2458–2463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Damhofer H, Veenstra VL, Tol JA, van
Laarhoven HW, Medema JP and Bijlsma MF: Blocking Hedgehog release
from pancreatic cancer cells increases paracrine signaling potency.
J Cell Sci. 128:129–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
